The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
India's TB Prevalence Survey 2019-2021, the first of its kind in the country in 55 years, has found that tuberculosis (TB) is more prevalent in India than previously thought. 31 March 2022
The Ministry of Health has begun collecting data on drugs that are not produced in Russia as well as a number of “friendly” countries as part of its efforts to prevention their shortage in the domestic market, according to recent statements by an official spokesman of the Ministry and local media, reports The Pharma Letter’s local correspondent. 30 March 2022
Japanese pharma major Shionogi saw its shares gain 4.5% to 7,904 yen today announced a basic agreement with the Ministry of Health, Labor and Welfare (MHLW) for the supply of S-217622, an orally administered antiviral drug for COVID-19, in Japan. 25 March 2022
As well as offering a batch of proposals to relieve households facing a crippling cost of living crisis, UK Chancellor Rishi Sunak’s Spring Statement yesterday included a number of relevant announcements for the pharmaceutical industry. 24 March 2022
The federal government of Australia will invest A$28.1 million ($20.9 million) into a new agency for the Health Portfolio, Genomics Australia, it has been announced. 22 March 2022
In support of US President Joe Biden’s Cancer Moonshot℠goal of fostering data sharing in cancer research, the National Cancer Institute, part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. 22 March 2022
Australian cancer patients will get improved access to local clinical trials through a new public-private partnership consortium, PrOSPECT, which today announced a funding agreement that is expected to enable a significant increase in local cancer clinical trial participation. 17 March 2022
The Indian government has extended the application date till March-end for the PLI (production linked incentive) scheme for bulk drugs. The government said that after two rounds of inviting applications, a total 49 projects have been approved for 33 critical APIs with a committed investment of $483 million. 16 March 2022
New Zealand’s Pharmaceutical Management Agency (Pharmac) has just released its Options for Investment (OFI) list, which includes 36 new medicines since it was updated in July 2021. The OFI includes all medicines that Pharmac would fund if its budget allowed. 10 March 2022
Pharmaceutical companies and vaccine makers in India who have developed potential vaccine candidates against dengue are in for some good times, with the Indian Council of Medical Research (ICMR) inviting domestic pharma companies to collaborate on the development of the country’s first vaccine for dengue. 8 March 2022
In London, the Global Pandemic Preparedness Summit is bringing together new sources of funding while aiming to boost cooperation between countries and healthcare organizations in the face of possible future threats. 8 March 2022
The COVID-19 pandemic has highlighted the critical link between patient access to medicine and a robust medicines manufacturing sector. As health systems begin to recover from the pandemic, a new crisis threatens stability and secure supply of medicines in Europe. 7 March 2022
The European pharma industry has responded to a “non-legislative resolution” detailing plans and actions to move away from using animals in medical research. 7 March 2022
Following the Russian invasion against Ukraine and in solidarity with the people of Ukraine, the European Commission said today it has decided to suspend the cooperation with Russian entities in research, science and innovation. 4 March 2022
Australian patients will have improved access to clinical trials due to reforms to be introduced by the Australian government, following advocacy by pharma trade lobby Medicines Australia and other groups. 4 March 2022
The US medicines regulator has issued three final guidances to drugmakers regarding cancer clinical trials, reflecting a broader push from the administration to improve healthcare outcomes in oncology. 2 March 2022